Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
Moleculin Biotech (MBRX) Stock Price & Analysis
1,328 Followers
MBRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.35 - $15.76
Previous Close$3.45
Volume2.98K
Average Volume (3M)23.89K
Market Cap
$7.97M
Enterprise Value-$15.10M
Total Cash (Recent Filing)$23.55M
Total Debt (Recent Filing)$474.00K
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 14, 2024EPS Estimate
-$2.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.98
Shares Outstanding2,311,536
10 Day Avg. Volume32,070
30 Day Avg. Volume23,893
Standard Deviation0.20
R-Squared0.24
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.58
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda2.53
Forecast
1Y Price Target
$30.00Price Target Upside740.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Moleculin Biotech News
PremiumCompany Announcements
Moleculin Biotech Announces Promising Annamycin Trial Results
PremiumCompany Announcements
Moleculin Biotech to Present Research at EHA2024 Hybrid Congress
PremiumCompany Announcements
Moleculin Biotech Initiates Phase 2 Glioblastoma Treatment Study
PremiumCompany Announcements
Moleculin Biotech Updates Investors with Corporate PresentationBulls Say, Bears Say
Bulls Say
EfficacyAnnamycin's complete remission rate in second-line patients is 50%, significantly higher than the 20%-25% range for approved therapies.
Regulatory SupportGiven the compelling data and lack of cardiotoxicity, regulators are expected to be supportive of a path to a pivotal trial.
SafetyOver 82 patients across 5 clinical trials have not experienced cardiotoxicity, supporting the likelihood of regulatory approval for a pivotal trial.
Bears Say
EarningsMoleculin reported a net loss of $4.9 million.
Financial PerformanceMoleculin filed its 10-K and reported a net loss of $10.3 million.
Price TargetPrice target lowered to $20 from $45 due to anticipated dilution from future capital raises needed to advance Annamycin.
---
Ownership Overview
3.91% Insiders
13.37% Mutual Funds
10.24% Other Institutional Investors
72.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $3.35 and its highest was $15.76 in the past 12 months.
What is Moleculin Biotech’s market cap?
Currently, no data Available
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Aug 14, 2024 which is in 42 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on May 13, 2024. The company reported -$2.02 earnings per share for the quarter, beating the consensus estimate of -$3.53 by $1.51.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -$2.51.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 2,311,536 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$2.02 in its last earnings report, beating expectations of -$3.53. Following the earnings report the stock price went down -1.891%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
---
Moleculin Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (740.34% Upside)
$30.00 (740.34% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.26%
12-Months-Change
Fundamentals
Return on Equity
-79.75%
Trailing 12-Months
Asset Growth
-39.59%
Trailing 12-Months
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
---
MBRX Earnings Call
Q1 2024
0:00 / 0:00
---
MBRX Stock 12 Month Forecast
Average Price Target
$30.00
▲(740.34% Upside)
Technical Analysis
Best Analysts Covering MBRX
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-44.31%
reiterated a buy rating 16 days ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -44.31% per trade.
---